MarketPulse

gotistobart

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Biontech Se

BioNTech to Unveil Late-Stage Oncology Breakthroughs at 2026 ASCO Meeting

BioNTech advances 25+ late-stage oncology trials with promising pumitamig and gotistobart data set for 2026 ASCO presentation, signaling successful pipeline diversification beyond COVID vaccines.
BMYCELGrBNTXclinical trialsoncology pipeline
GlobeNewswire Inc.GlobeNewswire Inc.··Biontech Se

BioNTech Advances Late-Stage Oncology Pipeline With ASCO 2026 Clinical Data

BioNTech presents Phase 2 Pumitamig and Gotistobart survival data at ASCO 2026, advancing 25+ Phase 2/3 oncology trials including 13 registration-relevant studies.
BMYCELGrBNTXclinical trialsoncology pipeline